Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition.

ABSTRACT:

Purpose

Myelotoxicity is a well-known adverse effect of alkylating chemotherapy for glioblastoma. While risk factors during first-line therapy are established, little is known about myelotoxicity recurrence in second-line treatment. This study investigates whether first-line myelotoxicity therapy predisposes patients to recurrence in the second-line setting.

Patients and methods

We conducted a retrospective cohort study of 589 patients with glioblastoma treated at the Brain Tumor Centre Amsterdam (2005-2022). Of these, 178 received second-line lomustine or rechallenge temozolomide. Myelotoxicity severity was predominantly assessed using nadir hematological values and its duration. A log-link generalized linear model evaluated associations between first-line and second-line m

SUBMITTER: van Hout L 

PROVIDER: S-EPMC12832940 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature